Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Safety & Efficacy Study of Perifosine + Bortezomib +/- Dexamethasone for Multiple Myeloma Patients

This study has been completed.
Information provided by (Responsible Party):
Keryx / AOI Pharmaceuticals, Inc. Identifier:
First received: November 15, 2006
Last updated: February 7, 2012
Last verified: February 2012